These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 3229945)

  • 1. A phase II study of VP-16 and cisplatin in patients with unresectable malignant mesothelioma. An NCI Canada Clinical Trials Group Study.
    Eisenhauer EA; Evans WK; Murray N; Kocha W; Wierzbicki R; Wilson K
    Invest New Drugs; 1988 Dec; 6(4):327-9. PubMed ID: 3229945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma.
    Planting AS; van der Burg ME; Goey SH; Schellens JH; van den Bent MJ; de Boer-Dennert M; Stoter G; Verweij J
    Ann Oncol; 1995 Jul; 6(6):613-5. PubMed ID: 8573543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of high-dose cisplatin in patients with malignant mesothelioma.
    Mintzer DM; Kelsen D; Frimmer D; Heelan R; Gralla R
    Cancer Treat Rep; 1985 Jun; 69(6):711-2. PubMed ID: 4040424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.
    Shin DM; Fossella FV; Umsawasdi T; Murphy WK; Chasen MH; Walsh G; Komaki R; McMurtrey MJ; Hong WK
    Cancer; 1995 Dec; 76(11):2230-6. PubMed ID: 8635025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura.
    Kasseyet S; Astoul P; Boutin C
    Cancer; 1999 Apr; 85(8):1740-9. PubMed ID: 10223568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force.
    Pennucci MC; Ardizzoni A; Pronzato P; Fioretti M; Lanfranco C; Verna A; Giorgi G; Vigani A; Frola C; Rosso R
    Cancer; 1997 May; 79(10):1897-902. PubMed ID: 9149015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma.
    Tsavaris N; Mylonakis N; Karvounis N; Bacoyiannis C; Briasoulis E; Skarlos D; Pavlidis N; Stamatelos G; Kosmidis P
    Lung Cancer; 1994 Sep; 11(3-4):299-303. PubMed ID: 7812707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
    Samuels BL; Herndon JE; Harmon DC; Carey R; Aisner J; Corson JM; Suzuki Y; Green MR; Vogelzang NJ
    Cancer; 1998 Apr; 82(8):1578-84. PubMed ID: 9554537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of six cases of mesothelioma with doxorubicin and cisplatin.
    Zidar BL; Pugh RP; Schiffer LM; Raju RN; Vaidya KA; Bloom RL; Horne D; Baker LH
    Cancer; 1983 Nov; 52(10):1788-91. PubMed ID: 6684983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura.
    Henss H; Fiebig HH; Schildge J; Arnold H; Hasse J
    Onkologie; 1988 Jun; 11(3):118-20. PubMed ID: 3045724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy with cisplatin and/or doxorubicin in malignant mesothelioma. A retrospective study [corrected from prospective].
    Tsavaris N; Primikirios N; Mylonakis N; Varouchakis G; Dosios T; Pavlidis N; Skarlos D; Tasopoulos T; Dritsas J; Kosmidis P
    Anticancer Res; 1997; 17(5B):3799-802. PubMed ID: 9427783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
    Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
    In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.
    Chahinian AP; Antman K; Goutsou M; Corson JM; Suzuki Y; Modeas C; Herndon JE; Aisner J; Ellison RR; Leone L
    J Clin Oncol; 1993 Aug; 11(8):1559-65. PubMed ID: 8336195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
    van Meerbeeck JP; Gaafar R; Manegold C; Van Klaveren RJ; Van Marck EA; Vincent M; Legrand C; Bottomley A; Debruyne C; Giaccone G; ;
    J Clin Oncol; 2005 Oct; 23(28):6881-9. PubMed ID: 16192580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial.
    O'Brien ME; Watkins D; Ryan C; Priest K; Corbishley C; Norton A; Ashley S; Rowell N; Sayer R
    Ann Oncol; 2006 Feb; 17(2):270-5. PubMed ID: 16317014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma.
    Berghmans T; Lafitte JJ; Paesmans M; Stach B; Berchier MC; Wackenier P; Lecomte J; Collon T; Mommen P; Sculier JP;
    Lung Cancer; 2005 Oct; 50(1):75-82. PubMed ID: 16005104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pemetrexed-cisplatin combination in mesothelioma.
    Reck M; Gatzemeier U
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):231-7. PubMed ID: 15877521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP).
    Parra HS; Tixi L; Latteri F; Bretti S; Alloisio M; Gravina A; Lionetto R; Bruzzi P; Dani C; Rosso R; Cosso M; Balzarini L; Santoro A; Ardizzoni A
    Cancer; 2001 Aug; 92(3):650-6. PubMed ID: 11505411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination chemotherapy with cisplatin, carboplatin, and etoposide in advanced malignancy: a phase I trial.
    Rajkumar SV; Frytak S; Rubin J; Camoriano JK; Fitch TR
    Am J Clin Oncol; 1997 Oct; 20(5):500-4. PubMed ID: 9345336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study.
    Samson MK; Wasser LP; Borden EC; Wanebo HJ; Creech RH; Phillips M; Baker LH
    J Clin Oncol; 1987 Jan; 5(1):86-91. PubMed ID: 3543239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.